Divergent effects of angiotensin-converting enzyme inhibition on blood pressure and endothelial function in obese humans

Diabetes and Vascular Disease Research

Volumn 3, Issue 1, 2006, Pages 34-38

  Williams, Ian L ^a   Chowienczyk, Philip J ^a   Wheatcroft, Stephen B ^a   Patel, Ameet G ^b   Sherwood, Roy A ^a   Shah, Ajay M ^a   Kearney, Mark T ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Endothelial function; Obesity; Renin angiotensin system

Indexed keywords

CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; LIPID; PERINDOPRIL;

ADULT; ARTERIAL PRESSURE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; MALE; OBESITY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; ULTRASOUND;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; BRACHIAL ARTERY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; OBESITY; PERINDOPRIL; VASODILATION;

EID: 33745027687     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2006.004     Document Type: Article

References (29)

1. Rexrode KM, Carey VJ, Hennekens CH et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998;280:1834-48.
2. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-77.
3. Manson JE, Colditz GA, Stampfer MJ et al. A prospective study of obesity and risk of coronary heart disease in women. N Eng J Med 1990;322:882-9.
4. Williams IL, Wheatcroft SB, Shah AM, Kearney MT. Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes Relat Metab Disord 2002;26:754-64.
5. Williams IL, Chowienczyk PJ, Wheatcroft SB et al. Effect of fat distribution on endothelial-dependent and endothelial-independent vasodilatation in healthy humans. Diabetes Obes Metab 2006;8:296-301.
6. Creager MA, Cooke JP, Mendelsohn ME et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolaemic humans. J Clin Invest 1990;86:228-34.
7. Celermajer DS, Sorensen KE, Georgakopoulous D et al. Cigarette smoking is associated with a dose dependent and potentially reversible impairment of endothelium-dependent dilatation in healthy young adults. Circulation 1993;88:2149-55.
8. Clapp BR, Hingorani AD, Kharbanda RK et al. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res 2004;64:172-8.
9. Kataoka C, Egashira K, Inoue S et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodelling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 2002;39:245-50.
10. Tanner FC, Meier P, Greutert H et al. Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation 2000;101:1982-9.
11. Kenagy RD, Clowes AW. Blockade of smooth muscle cell migration and proliferation in baboon aortic explants by interleukin-1beta and tumor necrosis factor-alpha is nitric oxide-dependent and nitric oxide-independent. J Vasc Res 2000;37:381-9.
12. Cornwell TL, Arnold E, Boerth NJ et al. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 1994;267:C1405-C1413.
13. Monastyrskaya E, Folarin N, Malyshev I et al. Application of the nitric oxide donor SNAP to cardiomyocytes in culture provides protection against oxidative stress. Nitric Oxide 2002;7:127-31.
14. Schafe, A, Wiesmann F, Neubauer S et al. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 2004;109:1819-22.
15. 1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002;40:521-7.
16. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
17. Bugiardini R, Manfrini O, Pizzi C et al. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation 2004;109:2518-23.
18. Williams IL, Chowienczyk PJ, Wheatcroft SB et al. Endothelial function and weight loss in obese humans. Obesity Surgery 2005;7:1055-60.
19. Ross, R. Atherosclerosis is an inflammatory disease. N Eng J Med 1999;340:115-26.
20. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part I: oxidative stress and atherogenesis. Circulation 2002;105:393-6.
21. Schling P, Mallow H, Trindl A, Loffler G. Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int J Obes Rel Metab Disord 1999;23:336-41.
22. Egan BM, Stepniakowski K, Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinaemic effects of salt restriction greater in subjects with risk factor clustering. Am J Hypertens 1994;7:886-93.
23. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
24. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Lancet 2000;355:253-9.
25. Svensson P, de Faire U, Sleight S et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001;38:E28-E32.
26. Bijlstra B, Smits P, Lutterman JA, Thien T. Effect of long-term angiotensin-converting enzyme inhibition in patients with the insulin resistance syndrome. J Cardiovasc Pharmacol 1995;25:658-64.
27. O'Driscoll G, Green D, Maiorana A et al. Improvement in endothelial function by angiotensin converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1999;33:1506-11.
28. Lyons D, Webster J, Benjamin N. The effect of antihypertensive therapy on responsiveness to local intra-arterial NG-monomethyl-L-arginine in patients with essential hypertension. J Hypertens 1994;12:1047-52.
29. 1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003;16:123-8.